Purple Biotech Ltd. (PPBT)

NASDAQ: PPBT · IEX Real-Time Price · USD
0.820
+0.120 (17.14%)
Feb 29, 2024, 3:35 PM EST - Market open

Total Valuation

Purple Biotech has a market cap or net worth of $18.38 million. The enterprise value is $2.67 million.

Market Cap 18.38M
Enterprise Value 2.67M

Important Dates

The next estimated earnings date is Tuesday, March 12, 2024, before market open.

Earnings Date Mar 12, 2024
Ex-Dividend Date n/a

Share Statistics

Purple Biotech has 28.91 million shares outstanding.

Shares Outstanding 28.91M
Owned by Insiders (%) 4.08%
Owned by Institutions (%) 9.44%
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 0.48
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 0.13
EV / Sales n/a
EV / EBITDA 0.12
EV / EBIT 0.13
EV / FCF n/a

Financial Position

The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.01.

Current Ratio 2.69
Quick Ratio n/a
Debt / Equity 0.01
Debt / EBITDA 0.02
Debt / FCF n/a
Interest Coverage 116.73

Financial Efficiency

Return on equity (ROE) is 48.10% and return on invested capital (ROIC) is -58.01%.

Return on Equity (ROE) 48.10%
Return on Assets (ROA) 41.90%
Return on Capital (ROIC) -58.01%
Revenue Per Employee n/a
Profits Per Employee $1.05M
Employee Count 20
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -65.36% in the last 52 weeks. The beta is 0.56, so Purple Biotech's price volatility has been lower than the market average.

Beta (1Y) 0.56
52-Week Price Change -65.36%
50-Day Moving Average 0.74
200-Day Moving Average 1.14
Relative Strength Index (RSI) 52.82
Average Volume (30 Days) 91,837

Short Selling Information

Short Interest 315,357
Short Previous Month 418,056
Short % of Shares Out 6.95%
Short % of Float n/a
Short Ratio (days to cover) 5.62

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -22.61M
Pretax Income 21.06M
Net Income 21.06M
EBITDA 21.44M
EBIT 21.25M
Earnings Per Share (EPS) -$1.05
Full Income Statement

Balance Sheet

The company has $16.08 million in cash and $370,000 in debt, giving a net cash position of $15.71 million or $0.54 per share.

Cash & Cash Equivalents 16.08M
Total Debt 370,000
Net Cash 15.71M
Net Cash Per Share $0.54
Equity / Book Value 38.60M
Book Value Per Share 1.34
Working Capital 10.50M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$14.94 million and capital expenditures -$3,000, giving a free cash flow of -$14.95 million.

Operating Cash Flow -14.94M
Capital Expenditures -3,000
Free Cash Flow -14.95M
FCF Per Share -$0.75
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -11.37%
Shareholder Yield -11.37%
Earnings Yield 114.59%
FCF Yield -81.31%

Analyst Forecast

The average price target for Purple Biotech is $9.67, which is 1,079.27% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.67
Price Target Difference 1,079.27%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on August 21, 2020. It was a reverse split with a ratio of 1:10.

Last Split Date Aug 21, 2020
Split Type Reverse
Split Ratio 1:10

Scores

Altman Z-Score n/a
Piotroski F-Score 3